CNS Pharmaceuticals, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that CNS Pharmaceuticals, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Net Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($3.22M) | Nov 14, 2025 |
| Q3 | 2025 | Jun 30, 2025 | ($2.37M) | Nov 14, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($2.37M) | Aug 14, 2025 |
| Q2 | 2025 | Mar 31, 2025 | ($4.30M) | Aug 14, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($4.30M) | May 15, 2025 |
| Q3 | 2025 | Mar 31, 2025 | ($4.30M) | Nov 14, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($5.61M) | Nov 14, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($2.53M) | Aug 14, 2025 |
| Q3 | 2025 | Jun 30, 2024 | ($2.53M) | Nov 14, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($3.54M) | May 15, 2025 |
| Q3 | 2025 | Mar 31, 2024 | ($3.54M) | Nov 14, 2025 |
| Q2 | 2025 | Mar 31, 2024 | ($3.54M) | Aug 14, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($4.52M) | Nov 14, 2024 |
| Q3 | 2024 | Jun 30, 2023 | ($4.02M) | Nov 14, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($4.02M) | Aug 14, 2024 |
| Q2 | 2024 | Mar 31, 2023 | ($4.93M) | Aug 14, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($4.93M) | May 15, 2024 |
| Q3 | 2024 | Mar 31, 2023 | ($4.93M) | Nov 14, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($3.42M) | Nov 14, 2023 |
| Q3 | 2023 | Jun 30, 2022 | ($3.57M) | Nov 14, 2023 |
Operating Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($3.25M) | Nov 14, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($2.41M) | Aug 14, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($4.34M) | May 15, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($5.63M) | Nov 14, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($2.53M) | Aug 14, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($3.54M) | May 15, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($4.53M) | Nov 14, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($4.03M) | Aug 14, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($4.93M) | May 15, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($3.42M) | Nov 14, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($3.56M) | Aug 14, 2023 |
| Q1 | 2023 | Mar 31, 2022 | ($3.15M) | May 15, 2023 |
| Q3 | 2022 | Sep 30, 2021 | ($3.81M) | Nov 10, 2022 |
| Q2 | 2022 | Jun 30, 2021 | ($3.81M) | Aug 12, 2022 |
| Q1 | 2022 | Mar 31, 2021 | ($3.61M) | May 13, 2022 |
| Q3 | 2021 | Sep 30, 2020 | ($2.01M) | Nov 12, 2021 |
| Q2 | 2021 | Jun 30, 2020 | ($2.47M) | Aug 13, 2021 |
| Q1 | 2021 | Mar 31, 2020 | ($1.97M) | May 13, 2021 |
| Q3 | 2020 | Sep 30, 2019 | ($699.1K) | Nov 12, 2020 |
| Q2 | 2020 | Jun 30, 2019 | ($415.1K) | Aug 10, 2020 |